In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.
about
Global Molecular Epidemiology of Cryptococcus neoformans and Cryptococcus gattii: An Atlas of the Molecular TypesCryptococcus gattii infectionsTime-course proteome analysis reveals the dynamic response of Cryptococcus gattii cells to fluconazoleSpecies in the Cryptococcus gattii Complex Differ in Capsule and Cell Size following Growth under Capsule-Inducing ConditionsCryptococcal meningitis: epidemiology and therapeutic options.Antifungal drug susceptibility and phylogenetic diversity among Cryptococcus isolates from dogs and cats in North America.Rapid identification of Cryptococcus neoformans and Cryptococcus gattii by matrix-assisted laser desorption ionization-time of flight mass spectrometry.Regulatory circuitry governing fungal development, drug resistance, and disease.Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based method for discrimination between molecular types of Cryptococcus neoformans and Cryptococcus gattiiMALDI-TOF MS enables the rapid identification of the major molecular types within the Cryptococcus neoformans/C. gattii species complex.Galleria mellonella model identifies highly virulent strains among all major molecular types of Cryptococcus gattiiMethod for identification of Cryptococcus neoformans and Cryptococcus gattii useful in resource-limited settings.Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.MLST and Whole-Genome-Based Population Analysis of Cryptococcus gattii VGIII Links Clinical, Veterinary and Environmental Strains, and Reveals Divergent Serotype Specific Sub-populations and Distant Ancestors.Identification and Characterization of VNI/VNII and Novel VNII/VNIV Hybrids and Impact of Hybridization on Virulence and Antifungal Susceptibility Within the C. neoformans/C. gattii Species ComplexCryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.Cryptococcus gattii as an important fungal pathogen of western North America.Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.Fluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11.Cryptococcus gattii: where do we go from here?Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.Fatal Cryptococcus gattii genotype AFLP6/VGII infection in a HIV-negative patient: case report and a literature review.Impact of Resistance to Fluconazole on Virulence and Morphological Aspects of Cryptococcus neoformans and Cryptococcus gattii Isolates.In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.Equine Pulmonary Cryptococcosis: A Comparative Literature Review and Evaluation of Fluconazole Monotherapy.HIV/AIDS-Associated Cryptococcosis in Portugal Spanning the Pre- to Post-HAART Era: A Retrospective Assessment at the Genotypic Level Based on URA5-RFLP.First case of mixed infection with Cryptococcus deuterogattii and Cryptococcus neoformans VNI in an Ivorian HIV-positive patient.Diversity and Antifungal Drug Susceptibility of Cryptococcus Isolates in Thailand.Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico.Rapid identification of Cryptococcus neoformans var. grubii, C. neoformans var. neoformans, and C. gattii by use of rapid biochemical tests, differential media, and DNA sequencing.First molecular typing of cryptococcemia-causing cryptococcus in central-west Brazil.Polymorphism in Mitochondrial Group I Introns among Cryptococcus neoformans and Cryptococcus gattii Genotypes and Its Association with Drug Susceptibility.A decade of experience: Cryptococcus gattii in British Columbia.Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis.Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex.Otogenic meningoencephalomyelitis due to Cryptococcus gattii (VGII) infection in a cat from Western Australia.MLST reveals a clonal population structure for Cryptococcus neoformans molecular type VNI isolates from clinical sources in Amazonas, Northern-Brazil.Antifungal Susceptibility Testing of Candida and Cryptococcus Species and Mechanisms of Resistance: Implications for Clinical LaboratoriesInsights on the Genotype Distribution Among Cryptococcus neoformans and C. gattii Portuguese Clinical Isolates
P2860
Q21284793-B11B65A6-850B-4287-B038-6A0A698A692AQ27002687-DD310022-3145-4C4A-85E2-12FEF514317BQ28482096-D3FFCBBE-A50C-4B3B-AAB2-255DD646061CQ28818460-BFF60BA7-6DBD-4DC8-AC64-051BD260C553Q33633343-ACC150F9-9DFA-4FBC-A1F3-3A76DF607E3BQ33703525-D8CCFD92-8C17-416B-B9FB-0FC7E15E8644Q33926640-6F4C7E2E-0733-4FFA-8278-B353AA63A624Q34190284-C730522E-B2A8-471F-9F91-4F0431DE27E8Q34264267-DC54A3B0-656C-4714-BD86-E118105D399DQ34292528-5CB6BB00-BD03-4420-A625-D823BE9F4E5AQ35227221-4FA87030-FDA6-479F-938A-D10368631040Q35849459-4432A238-A069-4416-998F-4E5D0F6CA69EQ36018713-3644C654-D1D0-4E29-999C-5E6D6CD1D813Q36095849-5FB3D413-1B51-4122-B0D8-B7583007DDDCQ36168992-B242BB6A-806C-4116-9408-4FFA53D0A8DBQ36364064-6398CE88-D72E-41EA-B5AD-A235A7E39E4CQ36404905-9482E0F1-5D4B-4F19-8186-0ACB03CCD6FAQ36440166-8793BF9E-BC64-441E-BED7-5B89994D40BDQ36644733-EE9F0424-BB4D-4994-8A66-862284954DBDQ37937029-61CC1818-731A-4B7C-A970-9A01CB99501FQ38154164-357736C3-15DF-49FF-B15D-751F8B56D6EEQ38224820-E379A881-7F34-4DC9-8BBE-4B5984570A09Q38467366-B17D77E2-34FA-4372-9EB3-72C0593A72B5Q38547201-2B17AA9F-AAA0-4449-8D77-25CC103AF3D0Q38961238-3D1AE46F-9354-4BD9-AA5B-C21C660897E3Q39202141-99008F1E-97E4-4BA3-9696-164DB2D9F675Q40276142-8379063C-803F-498F-B166-A67F3D6C3BB0Q40424785-DAFA955D-CB8F-4773-859C-49123B0DA5A4Q40796391-24335C6F-8149-4589-8CE1-19E162E5B3CEQ41643640-CB2445B7-0336-4253-A67A-A766F2C3E4BCQ42850204-C8E49A3A-21EF-4E41-9E31-4198672F45BCQ44611332-5D190EA7-8F4E-4E31-98B2-36D65BB49010Q50322018-941104D5-660A-4CD9-A70A-81EE6FD52200Q51583671-3A60E9FB-BE71-4D9B-92C0-2981210C2E4DQ53685613-0A792D5E-B576-42C3-9F50-EF0D6144C76FQ53841326-F5FF1C1B-6552-4D79-8A73-28AE796A3CA7Q54961481-530FDDA8-F4CD-45B7-BC65-18A15B034A0DQ55214082-E7C2AFB0-6359-48A2-8B00-F7B71A462885Q57745988-750A07DD-A021-4CC5-87FB-09DFE4C9353DQ58034718-A3CDC5EC-7F89-4E4A-B47A-D7490AB3732C
P2860
In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
In vitro susceptibility of the ...... aries with molecular genotype.
@ast
In vitro susceptibility of the ...... aries with molecular genotype.
@en
In vitro susceptibility of the ...... aries with molecular genotype.
@nl
type
label
In vitro susceptibility of the ...... aries with molecular genotype.
@ast
In vitro susceptibility of the ...... aries with molecular genotype.
@en
In vitro susceptibility of the ...... aries with molecular genotype.
@nl
prefLabel
In vitro susceptibility of the ...... aries with molecular genotype.
@ast
In vitro susceptibility of the ...... aries with molecular genotype.
@en
In vitro susceptibility of the ...... aries with molecular genotype.
@nl
P2093
P2860
P356
P1476
In vitro susceptibility of the ...... aries with molecular genotype.
@en
P2093
Hin Siong Chong
Rebecca Dagg
Richard Malik
Sharon Chen
P2860
P304
P356
10.1128/JCM.01271-10
P407
P50
P577
2010-09-15T00:00:00Z